Increased demands for faster high-throughput CRISPR-based cell-line development and improved pharmaceutical screening are encouraging research facilities and companies to automate their labs.
To ensure the stability and usability of injectable biopharmaceutical products, protein aggregation and active principle ingredients are of the utmost concern.
To control C auris, focus on using antibiotics and improving diagnostics. New treatments in development offer hope for better management. This is the fourth and final installment in CDC's interview with the ICT.